ClinicalTrials.gg
CompletedNCT06244589Updated May 29, 2024

Evaluation of Risk Factors Leading to Conversion From Laparoscopic Cholecystectomy to Open Surgery

An interventional study of Laparoscopic cholecystectomy and Open-conversion cholecystectomy in Cholelithiasis, Cholecystitis, Acute and Cholecystitis, Chronic, sponsored by Sisli Hamidiye Etfal Training and Research Hospital. Completed at 1 site in Turkey. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2024-05-29.

Sponsored by Sisli Hamidiye Etfal Training and Research Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
1,695
Allocation
Non-randomized
Ages
18 Years to 95 Years
Sex
All
01

Study summary

This retrospective controlled study aims to evaluate risk factors that affect open conversion in laparoscopic cholecystectomy. Patient characteristics, medical history, biochemical and radiological studies of the patient will searched from the hospital database and factors affecting open conversion will be analysed.

Read the detailed description

Cholecystectomy is a commonly performed procedure in general surgical practice, and with advancements in technology, it is widely conducted using the laparoscopic method. Despite the decreasing trend in open surgical procedures with increasing experience and technological developments, the literature reports conversion to open surgery in laparoscopic cholecystectomy ranging from 2% to 15%. Although some studies exist regarding patient groups at risk of conversion to open surgery, the current literature is insufficient to draw a clear conclusion on this matter. This study aims to evaluate risk factors for conversion to open surgery by examining cases of laparoscopically initiated cholecystectomy.

The study will be conducted retrospectively by reviewing archive records. Patients operated for cholecystectomy will be included. Patients that open surgical method used from start will be excluded from study. Age, comorbidities (ASA score), laboratory findings (leukocyte count and CRP), imaging findings (abdominal ultrasound, CT, or MRI), history of previous abdominal surgery, history of ERCP, and history of pancreatitis will be evaluated. Laparoscopic cholecystectomy cases will be compared with open-conversion cholecystectomies to assess factors influencing the conversion.

02

Conditions studied

  • Cholelithiasis
  • Cholecystitis, Acute
  • Cholecystitis, Chronic
  • Gallbladder Diseases

Keywords

  • Laparoscopic cholecystectomy
  • Conversion
  • Cholelithiasis
  • Acute cholecystitis
03

In context

Cholelithiasis

189 studies on the registry are indexed under Cholelithiasis; 42 are open to participants now.

This study's enrollment of 1,695 is above the median of 90 across 135 interventional studies indexed under Cholelithiasis.

Browse Cholelithiasis studies →

Lead sponsor

Sisli Hamidiye Etfal Training and Research Hospital is the lead sponsor of 114 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 95 years old.
  • Operated for gallbladder disease (Cholecystectomy)
  • Surgery must started with laparoscopic approach

Exclusion criteria

Exclusion Criteria:

  • Open surgery from the start
  • Cholecystectomy as a part of bigger surgical intervention (Such as pancreaticoduodenectomy)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,695 participants (actual)

Study arms

  • Active comparator
    Laparoscopic cholecystectomy

    Cases that laparoscopic cholecystectomy performed without need for open-conversion

    Procedure: Laparoscopic cholecystectomy

  • Experimental
    Open-conversion cholecystectomy

    Cases converted to open surgery based on intraoperative findings.

    Procedure: Laparoscopic cholecystectomy · Procedure: Open-conversion cholecystectomy

Interventions

  • ProcedureLaparoscopic cholecystectomy

    Laparoscopic cholecystectomy: Cholecystectomy that performed with laparoscopic method

  • ProcedureOpen-conversion cholecystectomy

    Open-conversion cholecystectomy: Cases in which laparotomy (Generally right subcostal incision) was performed based on intraoperative findings.

06

What researchers measure

Primary outcomes

  1. Open-conversion rate

    The rate of cases converted to open surgery among all laparoscopic cholecystectomy cases.

    Time frame: Immediately after the surgery

Secondary outcomes

  1. Postoperative complication rate

    The rate of postoperative complications

    Time frame: 1 months after the surgery

  2. Incidental gallbladder malignancy rate

    The rate of incidentally diagnosed gallbladder cancer among all laparoscopic cholecystectomies in patients without a preoperative diagnosis.

    Time frame: 1 months after the surgery

07

Study locations

1 site
  • Sisli Hamidiye Etfal Research and Training Hospital
    Istanbul, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in May 2024, 3 months.

Of 54 non-industry interventional studies with no phase under Cholelithiasis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's 3 months is below that.

Counting every sponsor, half of 58 studies reached it within 15 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2024
First posted
Feb 6, 2024
StartActual
Feb 12, 2024
Primary completionActual
May 28, 2024
CompletionActual
May 28, 2024
Last update
May 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06244589
Responsible party
Burak Dincer (Burak Dinçer, MD, Sisli Hamidiye Etfal Training and Research Hospital) — Principal investigator
First posted
Feb 6, 2024
Start date
Feb 12, 2024
Primary completion
May 28, 2024
Completion
May 28, 2024
Last update
May 29, 2024

Study contacts

Burak Dincer, M.D.
principal investigator · Sisli Hamidiye Etfal Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion